MarketsandMarkets

Nasal Drug Delivery Technology Market Worth 64.20 Billion USD by 2021

Asia is projected to grow at the highest CAGR during the forecast period. Opportunities in the Asian market have attracted huge investments by major companies in the area of R&D activities. In addition, the region has low costs of labor and clinical trials, which has further served to draw market players to Asia.

 

Seattle, WA -- (SBWIRE) -- 03/17/2017 -- The report "Nasal Drug Delivery Technology Market by Dosage Form (Nasal Drops, Sprays, Powder, Gel), System (Multidose, Unit Dose, BI-Dose), Therapeutic Applications (Rhinitis, Congestion, Vaccinations), End User (Hospitals, Homecare) - Global Forecast to 2021", The global nasal drug delivery technology market is projected to reach USD 64.20 Billion by 2021 from USD 44.00 Billion in 2016, at a CAGR of 6.5% during the forecast period.

Browse 95 market data tables and 36 figures spread through 212 pages and in-depth TOC on "Nasal Drug Delivery Technology Market"

http://www.marketsandmarkets.com/Market-Reports/nasal-drug-delivery-technology-market-192818058.html

Early buyers will receive 10% customization on this report.

Increasing patient preference for nasal drug delivery as a result of easy administration & better efficacy and growing adoption of self-administration practices are some of the major factors driving the growth of the nasal drug delivery technology market.

Furthermore, growth among over-the-counter nasal drugs and increasing focus on alternative routes of drug delivery such as nasal drug delivery offer significant growth opportunities for player operating in the market. On the other hand, complications associated with the overuse of nasal sprays may restraint the growth of the market.

Download PDF Brochure@ http://www.marketsandmarkets.com/pdfdownload.asp?id=192818058

The nasal drug delivery technology market is segmented based on dosage form, therapeutic application, end user, system, container, and region. On the basis of therapeutic application, the market is segmented into allergic and non-allergic rhinitis, nasal congestion, vaccination, and other therapeutic applications (osteoporosis, pain management, and sexual dysfunction).

The allergic and non-allergic rhinitis segment is expected to register the highest CAGR during the forecast period. The high growth in this segment can primarily be attributed to the increasing prevalence of allergic and non-allergic rhinitis and growing preference for nasal drugs for its treatment.

On the basis of dosage form, the market is segmented into the sprays, drops & liquids, nasal powders, and nasal gels. In 2016, the nasal sprays segment is expected to account for the largest share of the market.

Request For Customization Of This Report: http://www.marketsandmarkets.com/requestCustomization.asp?id=192818058

The large share of this market segment can be attributed to factors such as increased patient compliance due to reduced irritation caused by dust and pollen, affordable prices of nasal sprays, and delivery of large doses of drugs.

On the basis of region, the nasal drug delivery technology market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). North America is further sub segmented into the U.S. and Canada; while Europe is further sub segmented into Germany, France, the U.K., and Rest of Europe (RoE); Asia is further sub segmented into Japan, China, India, and Rest of Asia (RoA). In 2016, North America is expected to dominate the market, followed by Europe. This growth can be attributed to the increasing prevalence of COPD, rising adoption of nasal drug delivery technology, and the significant presence of major market players in the U.S.

The nasal drug delivery technology is at a very nascent stage market, comprising of various players. Prominent players in the nasal drug delivery technology market include Merck & Co., Inc. (U.S.), Novartis AG (Switzerland), Johnson & Johnson Services, Inc. (U.S.), Pfizer, Inc. (U.S.), AstraZeneca plc. (U.S.), AptarGroup (U.S.), and GlaxoSmithKline plc (U.K.).

About MarketsandMarkets
MarketsandMarkets is the largest market research firm worldwide in terms of annually published premium market research reports. Serving 1700 global fortune enterprises with more than 1200 premium studies in a year, M&M is catering to multitude of clients across 8 different industrial verticals. We specialize in consulting assignments and business research across high growth markets, cutting edge technologies and newer applications. Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors.

M&M's flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. The new included chapters on Methodology and Benchmarking presented with high quality analytical infographics in our reports gives complete visibility of how the numbers have been arrived and defend the accuracy of the numbers.

We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.

Contact:
Mr. Rohan
MarketsandMarkets
701 Pike Street
Suite 2175, Seattle,
WA 98101, United States
Telephone No : 888-600-6441